Stadiul cunoaşterii.... - Gr.T. Popa
Stadiul cunoaşterii.... - Gr.T. Popa
Stadiul cunoaşterii.... - Gr.T. Popa
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Corelaţii clinice,imunohistochimice şi morfopatologice în unele tumori de ovar<br />
Coordonator ştiinţific:Prof.Dr.Zenovia Florentina Pricop<br />
__________________________________________________Doctorand:Ioana Buda<br />
57. Houck K, Nikrui N, Duska L – LMPtumors of the ovary: correlation of frozen and permanent histopathologic<br />
diagnosis, Obstet Gynecol, 2000;95:839-843<br />
58. Isola J, Kallioniemi OP, Korte JM, Wahlstrom T, Aine R, Helle M, et al. Steroid receptors and Ki-67 reactivity<br />
in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and<br />
patient survival. J Pathol 1990;162:295–301<br />
59. Jacobs 1. Screening for early ovarian cancer. Lancet 1988;2:171-2.<br />
60. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, <strong>Gr</strong>utzinskas JG, Oram D. Prevalence screening for<br />
ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Brit Med J. 306(6884):<br />
1030-4, Apr 1993.<br />
61. Jacobs, I., and Bast, R. C., Jr. (1989). The CA 125 tumour-associated antigen: A review of the literature. Hum.<br />
Reprod. 4(1), 1–12.<br />
62. Lambert-Messerlian, G. M., Steinhoff, M., Zheng, W., Canick, J. A., Gajewski, W. H., Seifer, D. B. et al.<br />
(1997). Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian<br />
cancer. Gynecol. Oncol. 65(3), 512–516.<br />
63. Lappohn, R. E., Burger, H. G., Bouma, J., Bangah, M., Krans, M., and de Bruijn, H. W. (1989). Inhibin as a<br />
marker for granulosa-cell tumors. N. Engl. J. Med. 321(12), 790–793..<br />
64. Lash R.H., Hart W.R., Intestinal adenocarcinomas metastatic to the ovaries: a clinicopathologic evaluation of 22<br />
cases, Am J.Surg Pathol, 1987, 11: 114-121<br />
65. Lauszus FF, Petersen AC, <strong>Gr</strong>eisen J, et al. <strong>Gr</strong>anulosa cell tumor of the ovary: a population-based study of 37<br />
women with stage I disease. Gynecol Oncol 2001;81:456–60.<br />
66. Lauszus FF, Petersen AC, <strong>Gr</strong>eisen J, Jakobsen A. <strong>Gr</strong>anulosa cell tumor of the ovary: a population-based study<br />
of 37 women with stage I disease. Gynecol Oncol 2001;81:4460– 546<br />
67. Makar AP, Kristensen GB, Nesland J, Bormer OP & Trope´ CG 1994 The expression of c-erbB-2 (HER-2/neu)<br />
oncogene in patients with invasive ovarian malignancies. International Journal of Gynecological Cancer 4 194–<br />
199.<br />
68. Miller BE, Barron BA, Wan JY. Prognostic factors in adult granulosa cell tumor of the ovary. Cancer. May 15<br />
1997;79(10):1951-5.<br />
69. Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotHERapeutics as antiangiogenics. J Clin<br />
Oncol 2001;19:1195–206.<br />
70. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, and Andersen AN. Infertility, fertility drugs, and invasive<br />
ovarian cancer: a case-control study. Fertil Steril. 67(6): 1005-12, 1997.<br />
71. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, ProvencHER D, Radice P, Evans G, Bishop<br />
S, Brunet J, Ponder BAJ, Klijn JGM. Oral contraceptives and the risk of HEReditary ovarian cancer. N Engl J<br />
Med, 339(7): 424-428, 1998.<br />
72. Nash J, Hall L, Ozols R, Young R, Smyth J & Hamilton T 1989a Estrogenic regulation and growth factor<br />
expression in human ovarian cancer in vitro. Proceedings of the American Assocaition for Cancer Research 30<br />
1189.<br />
73. Netter H.Frank,Atlas of human anatomy, 4 th edition,Elsevier 2006<br />
74. Page R. ChemotHERapeutic agents. In: Pazdur R, Hoskins WH, Wagman L, eds. Cancer Management: A<br />
Multidisciplinary Approach. 4th ed. Mellville, NY: PRR Incorporated; 2000:. 971-80.<br />
79
Change language